Opinion|Videos|July 23, 2024
Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- After frontline therapy in limited-stage small cell lung cancer (LS-SCLC), how do you determine the appropriate second-line and subsequent therapy?
- What patient-specific factors do you consider?
- Other than clinical trial enrollment, what would you consider for second-line treatment?
- Please briefly describe the SWOG umbrella protocol for ES-SCLC
- Can we personalize treatment by identifying molecular subtypes that may be more responsive to certain therapies than others?
- Please provide your insights on the potential for improved survival benefits with chemoimmunotherapy and consolidative thoracic radiotherapy in patients with ES-SCLC.
- What additional research should be conducted to further validate the use of CIT and cTRT in this patient population?
- Please briefly comment on key updates in SCLC recently presented at ASCO 2024 and discuss how these findings may impact the overall treatment landscape.
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 8/2
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
4
Sonrotoclax Is Active in Chinese R/R MCL Cohort of the BGB-11417-201 Trial
5